. .

-

.. , .. , .. , .. , ..
- . .. , ,

() , . () , 1/3 . , . , , CYP219, - , , , , , . 24- - , . , , .

: , , , -, .

---

-


IL
PAF (platelet-activating factor)
SAP c (symptom association probability)
SI (symptom index)

---

() . , II , . , , , , [1].

, , Albert 1839 ., Qunke 1879 . . Rossetti 1967 . [2]. , ( , , 1997 .) [3]. 2006 . , , / [4].

() , - / , / , (), (- ), () ( ) [46].

[4]: (), 6065% , , 3035% . .. , X  (-, 1994) [7].

( 10 ) - , . , XX , XXI , VI 1997 . [8].

, , (. 1), , 10% [9]. 13,3% [10], 23,6%, [11].

1. ( [911])

. , ( GERD Q) [12], , , 24- -, . , , () [5].

, , . , 30% [13].

. Y. Fujiwara . [14] , (2) , . , / [5].

, , 1040% [1517], 50% [18], . , 50% [19, 20].

. , (. 1).

 

. 1. ,
IL ; PAF (platelet-activating factor); ; ; ; .

, , : , , , [21, 22].

. <4 >1 , , 2 [23]. A. Bredenoord . [24] .

. CYP219 -450 . CYP219 85%, 13% 1 [25, 26]. CYP219 . , , 5 , [27]. CYP219 MDR1 (ABCB1), [28].

, , [29]. S. Rasmussen . [30], , , 30,7%. , W. Young . [31], . , , , 74,3 10,5% . -, (68,9%) - (48,6%). 41,9% 11,2% . C. Hsu . [32], , , , , .

, . R. Florian . [33] , IL-1β, IL-8, PAF. , IL-8 3 . PAF , IL-1β, PAF, , [34].

, , , , , . , , , , .

. 24- - . - , . , , , [35].

24- -. - . , , -. , - (, , , ), [36].

, . ( Z), , , (- ). () , , . (. 2).

 

. 2.
. ., 42 . ; ; ; .

, (, ) . Z=8002400 . , , . , , (. 3). . , 3000 , , 7000 (. 4) [37].

. 3. ()
. ., 50 . (); (); >4 ( ).

 

. 4. ()
. ., 32 . (); ().

- (symptom index SI) c (symptom association probability SAP) [38]. SI , , , . SI , , <50%. SAP , . , , SAP ≥95%. , SI ≥50% SAP ≥95%, .

, ( 723% ) (, ), [13, 3942], [5, 43]. 4 [44]. - , <4. ( <4) - , >4. - , , - (. . 3).

24- - , . IV (2016 .) [45] , , , , (majormotordisorders , - , , ) . 3 6 c 2 [45]. - SI SAP. SI (<50%) SAP (<95%), [46].

, , , . - , SAP, [45].

, IV . , , - ( ) . 3 6 c 2 [45].

, . E. Savarino . [47], 329 36% (SAP+) ( ), 40% SAP+ ( ) 24% (SAP) - , ( ).

, . , , . -, , , . , (SAP+) [45].

, 24- - (. 5) .

 

. 5. -

. , , , , . , , , .

, 10 5 , (IRP, DCI, CDP, DL, Break . 2) , . III (2015 .), (. 6 ) [48].

2. [48]

. * ; ** MMS Unisensor 36- .

 

. 6.
. ., 54 ., . DCI 3780 .. (), IRP 14 .. (), DL 7,8 ().

, - (, - ), ( , ) (minor disorders of peristalsis )[48]. ( ), (IRP ) ≥50% , DCI<450 ... , , , (. 7).

 

. 7.
C . ., 42 . IRP 15 .. (); DCI 85 .. (<450 ..)).

, , K. Wang . [49], 176 . 43% , .

, , [50].

, [51]. >10 . , , , (. 8). , , . , [39, 52].

 

. 8. [36]
.

[50]. , , . , . , (. 9) [53].

 

. 9.
C . ., 45 . : , .

, - . , C. Andolfi . [54], - . 524 . 152 (29%) . 152 . 9,5% 1, 49,2% II 6,4% III . 34,9% . 3 (2%) - , , , . . , , 1/3 . , /- , [54].

. Herregods . [35] - , 106 , , 65% , 35% ( , .).

, 24- - , . , , . 24- -- .

.

:

1. (). . . ; 2003.

2. Rossetti M. The reflux disease of the esophagus--clinical-surgical aspects. Hippokrates. 1967;38(3):92-97.

3. Dent J, Brun J, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ, Lauritsen K, Reynolds C, Shaw M, Talley NJ on behalf of the Genval Workshop Group An evidence-based appraisal of reflux disease management-the Genval Workshop Report. Gut 1999;44(suppl 2):S1S16. doi:10.1136/gut.44.2008.S1

4. Vakil N, Zanten S, Kahrilas P, Dent J, Jones R. Global Consensus Group The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101(8):1900-1920. doi:10.1111/j.1442-2050.2011.01271.x

5. .., .., .., .., .., .., .., .., .., .., .., .., .. . . , 2014.

6. .., .., .. . . .: ; 2011.

7. Dent J. Endoscopic grading of reflux oesophagitis: the past, present and future. Best Pract Res Clin Gastroenterol. 2008;22(4):585-599. doi:10.1016/j.bpg.2008.01.002

8. 6th United European Gastroenterology Week. Birmingham, United Kingdom, 18-23 October 1997. Abstracts. Gut. 1997;41(Suppl 3):A1-258,E1-61.

9. El-Serag H, Sweet S, Winchester C, Dent J. Update on the epidemiology of gastro- oesophageal reflux disease: a systematic review. Gut 2014;63:871-880. doi:10.1136/gutjnl-2012-304269

10. .., .., .., .., .., .. (). . 2011;83:45-50.

11. Bor S, Lazebnik L, Kitapcioglu G, Manannikof I, Vasiliev Y. Prevalence of gastroesophageal reflux disease in Moscow. Dis Esophagus. 2016;29(2):159-165. doi:10.1111/dote.12310

12. .., .., .., .., .., .., .. Gerd Q . . 2013;5:15-23.

13. Zerbib F, Roman S, Ropert A, des Varannes SB, Pouderoux P, Chaput U, Mion F, Vérin E, Galmiche JP, Sifrim D. Esophageal pH-impedance monitoring and symptom analysis in GERD: a study in patients off and on therapy. Am J Gastroenterol. 2006;101(9):1956-1963. doi:10.1111/j.1572-0241.2006.00711.x

14. Fujiwara Y, Higuchi K, Yamamori K, Watanabe Y, Shiba M, Watanabe T, Tominaga K, Oshitani N, Matsumoto T, Arakawa T. Pathogenesis and treatment of refractory gastroesophageal reflux disease in Japanese patients Nihon Rinsho. 2004;62(8):1510-1515.

15. Carlsson R, Dent J, Watts R, Riley S, Sheikh R, Hatlebakk J, Haug K, de Groot G, van Oudvorst A, Dalväg A, Junghard O, Wiklund I. Gastroesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol. 1998;10(2):119-124.

16. Crawley J, Schmitt C. How satisfied are chronic heartburn sufferers with their prescription medications? Results of the Patient Unmet Needs Study. J Clin Outcomes Manag. 2000;7:29-34.

17. Inadomi JM, McIntyre L, Bernard L, Fendrick AM. Stepdown from multipleto single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol. 2003;98(9):1940-1944. doi:10.1111/j.1572-0241.2003.07665.x

18. Cicala M, Emerenziani S, Guarino MP, Ribolsi M. Proton pump inhibitor resistance, the real challenge in gastroesophageal reflux disease. World J Gastroenterol 2013;19(39):6529-6535. doi:10.3748/wjg.v19.i39.6529

19. Scarpignato C. Poor effectiveness of proton pump inhibitors in non-erosive reflux disease: the truth in the end! Neurogastroenterol Motil. 2012;24(8):697-704. doi:10.1111/j.1365-2982.2012.01977.x

20. Kawami N, Iwakiri K, Sakamoto C. Pathophysiology and Treatment of PPI-resistant NERD. Nihon Rinsho. 2015;73(7):1197-1201.

21. Chey WD, Inadomi JM, Booher AM, Sharma VK, Fendrick AM, Howden CW. Primary-care physicians perceptions and practices on the management of GERD: results of a national survey. Am J Gastroenterol. 2005;100(6):1237-1242. doi:10.1111/j.1572-0241.2005.41364.x

22. Pezanoski J, Guanaratnam N, Cowen M. Correct and incorrect dosing of proton pump inhibitors and its impact on GERD symptoms. Gastroenterology. 2003;124(suppl.):128.

23. Peres de la Serna J, Ruiz de Leon A, Sevilla-Mantilla C. Acid breakthrough in GERD patients under proton pump inhibitors (PPI) treatment in a daily practice. Gut. 2007;56(suppl. 3):217.

24. Bredenoord A, Smout A. Therapy resistance of gastro-oesophageal reflux symptoms: acid reflux, non-acid reflux or no reflux. Ned Tijdschr Geneeskd. 2008;152(47):2548-52.

25. .. CYP219 Helicobacter pylori. . . . 2009;4:128-132.

26. .., .., .., .., .. -450 2C19 Helicobacter pylori. . . . 2008;3:78-85.

27. Ichikawa H, Sugimoto M, Sugimoto K, Andoh A Furuta T. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis. J Gastroenterol Hepatol. 2016;31(4):716-726. doi:10.1111/jgh.13233

28. Maev IV, Andreev DN, Kucheryavyi YuA, Dicheva DT. Host factors influencing the eradication rate of Helicobacter pylori. World Applied Sciences Journal. 2014;30:134-40. doi:10.5829/idosi.wasj.2014.30.mett.61

29. .., .., .. . . , . 2013;5:17-22.

30. Rasmussen S, Jensen T, Henriksen S, Haastrup P, Larsen P, Sondergaard J, Jarbol D. Overlap of symptoms of gastroesophageal reflux disease, dyspepsia and irritable bowel syndrome in the general population. Scand J Gastroenterol. 2015;50(2):162-169. doi:10.3109/00365521.2014.983157

31. Young W, Hye-Kyung J, Seong-Eun K, Sung-Ae J. Overlap of Erosive and Non-erosive Reflux Diseases With Functional Gastrointestinal Disorders According to Rome III Criteria. J Neurogastroenterol Motil, 2010;16(2):148-156. doi:10.5056/jnm.2010.16.2.148

32. Hsu C, Liu T, Wen S, Wang C, Yi C, Chen J, Lei W, Orr W, Fabio P, Chen C. Clinical, metabolic, and psychological characteristics in patients with gastroesophageal reflux disease overlap with irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2015;27(5):516-522. doi:10.1097/MEG.0000000000000334

33. Rieder F, Biancani P, Harnett K, Yerian L, Falk GW. Inflammatory mediators in gastroesophageal reflux disease: impact on esophageal motility, fibrosis, and carcinogenesis Am J Physiol Gastrointest Liver Physiol. 2010;298(5):G571-G581. doi:10.1152/ajpgi.00454.2009

34. Cicala M. Gastroesophageal reflux disease: Update on inflammation and symptom perception. World J Gastroenterol. 2013; 19(39):6523-6528. doi:10.3748/wjg.v19.i39.6523

35. Herregods T, Troelstra M, Weijenborg P, Bredenoord A, Smout A. Patients with refractory reflux symptoms often do not have GERD. Neurogastroenterol Motil. 2015;27(9):1267-1273. doi:10.1111/nmo.12620

36. .., .., .. : . Consillium medicum. 2013;15(8):30-34.

37. .., .. - . . . . , . .. .: -̻; 2013.

38. Yinan S, Xiao Y, Chen M. Predictors for proton pump inhibitor failure in non-erosive gastroesophageal reflux disease. J Gastroenterol Hepatol. 2013;28(suppl. 3):60.

39. .., .. . Consilium Medicum. . 2013;2:9-14.

40. .., .., .. (, 2013). . 2014;24(3):22-27.

41. Eun H, Lee D, Park K. Evaluation of efficacy of proton pump inhibitors in refractory gastroesophageal reflux disease. J Gastroenterol Hepatol. 2013;28(suppl. 3):290.

42. Mainie I, Tutuian R, Shay S, Vela M, Zhang X, Sifrim D, Castell DO. Acid and nonacid reflux in patients with persistent symptoms despite acid suppressive therapy. A multicentre study using combined ambulatory impedance-pH monitoring. Gut. 2006;55(10):1398-1402. doi:10.1136/gut.2005.087668

43. Katz PO, Gerson LB, Vela MF. Diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013;108:308-328. doi:10.1038/ajg.2012.444

44. Sifrim D, Castell D, Dent J, Kahrilas PJ. Gastroesophageal reflux monitoring: Review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut. 2004;53(7):1024-1031. doi:10.1136/gut.2003.033290

45. Aziz Q, Fass R, Gyawali C, Miwa H, Pandolfino J, Zerbib F. Functional Esophageal Disorders. Gastroenterology 2016;150:1368-1379. doi:10.1053/j.gastro.2016.02.012

46. .., .. . . 2015;28:1682-1683.

47. Savarino E, Zentilin P, Tutuian R, Pohl D, Gemignani L, Malesci A, Savarino V. Impedance-pH reflux patterns can differentiate non-erosive reflux disease from functional heartburn patients. J Gastroenterol. 2012;47:159-168. doi:10.1007/s00535-011-0480-0

48. Kahrilas PJ, Bredenoord AJ, Fox M, Gyawali CP, Roman S, Smout AJ, Pandolfino JE. The Chicago Classification of esophageal motility disorders, v3.0. Neurogastroenterol Motil 2015;27:160-174. doi:10.1111/nmo.12477

49. Wang K, Duan L, Xia Z, Xu Z, Ge Y. Esophageal motility characteristics of refractory heartburn: a study based on high resolution manometry and 24 hour pH-impedance monitoring. Zhonghua Yi Xue Za Zhi. 2014;94(34):2650-2655.

50. Boeckxstaens G. Alterations confined to the gastro-oesofageal junction: the relationship between low LOSP, TLOSRs, hiatus hernia and acid pocket. Best Practice and Research Clinical Gastroenterology. 2010;24:821-829. doi:10.1016/j.bpg.2010.08.011

51. Pandolfino JE, Zhang QG, Ghosh SK, Han A, Boniquit C, Kahrilas PJ. Transient lower esophageal sphincter relaxations and reflux: mechanistic analysis using concurrent fluoroscopy and high-resolution manometry. Gastroenterology. 2006;131:1725-1733. doi:10.1053/j.gastro.2006.09.009

52. Grossi L, Ciccaglione A, Travaglini N, Marzio L. Transient lower esophageal sphincter relaxations and gastroesophageal reflux episodes in healthy subjects and GERD patients during 24 hours. Dig Dis Sci. 2001;46(4):815-821.

53. Bredenoord A, Weusten B, Carmagnola S, Smout A. Double-peaked high-pressure zone at the esophagogastric junction in controls and in patients with a hiatal hernia: a study using high-resolution manometry. Dig Dis Sci. 2004;49(7-8):1128-1135.

54. Andolfi C, Bonavina L, Kavitt R, Konda V, Asti E, Patti M. Importance of Esophageal Manometry and pH Monitoring in the Evaluation of Patients with Refractory Gastroesophageal Reflux Disease: A Multicenter Study. J Laparoendosc Adv Surg Tech. A. 2016 May 24. [Epub ahead of print]. doi:10.1089/lap.2016.018  

.., .., .., .., .. - // . 2017;89(2): 76-83. DOI:10.17116/terarkh201789276-83

http://www.gastroscan.ru